Project Details
Description
The study is a randomized, double-blind, and positive-controlled Phase III booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with either one dose of Sinopharm inactivated COVID-19 vaccine (Cohort 1) or one dose of Comirnaty (Cohort 2).
Layman's description
Approximately 1,800 participants aged 18 years old and above will be enrolled in this study. 1,350 participants who previously received Sinopharm inactivated COVID-19 vaccine will be enrolled to Cohort 1. 450 participants who previously received mRNA COVID-19 vaccine or previously diagnosed with COVID-19 will be enrolled to Cohort 2.
| Status | Finished |
|---|---|
| Effective start/end date | 30/05/22 → 1/05/23 |
Collaborative partners
- Sinocelltech Ltd. (lead)
Keywords
- COVID-19
- SARS-CoV-2
- Vaccine
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.